Dolutegravir resistance very rare after a switch – even with detectable HIV

Back to the "HIV and Co-Infections News" list

The emergence of high-level dolutegravir resistance was extremely rare in people switched to first-line dolutegravir-based treatment in Zambia and Malawi, a large prospective study has found.

But the risk of having unsuppressed HIV one and two years after switching was six to seven times higher in people who switched to dolutegravir with detectable HIV. The researchers say their findings emphasise the importance of viral load monitoring before switching.

Read the full story at Aidsmap.


Source : Aidsmap

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.